{"nctId":"NCT00325403","briefTitle":"FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)","startDateStruct":{"date":"2006-10"},"conditions":["Pulmonary Hypertension"],"count":349,"armGroups":[{"label":"UT-15C (oral treprositnil)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oral treprostinil (UT-15C) Sustained Release Tablets"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Oral treprostinil (UT-15C) Sustained Release Tablets","otherNames":["treprostinil diethanolamine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Between 12 and 75 years of age, inclusive.\n* Body weight at least 40 kg with a Body Mass Index \\< 45\n* PAH that is either idiopathic/heritable; associated with repaired congenital systemic-to-pulmonary shunts (repaired â‰¥ 5 years); associated with collagen vascular disease; associated with HIV.\n* Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.\n* Baseline 6-minute walk distance between 200 and 425 meters, inclusive.\n* Reliable and cooperative with protocol requirements.\n\nExclusion Criteria:\n\n* Nursing or pregnant.\n* Currently receiving an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or prostacyclin within 30 days of Baseline.\n* PAH due to conditions other than noted in the above inclusion criteria.\n* History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.\n* Use of an investigational drug within 30 days of Baseline.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Six Minute Walk Distance (6MWD)","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS).\n\nThe six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Six Minute Walk Distance (6MWD)","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration.\n\nThe six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Six Minute Walk Distance (6MWD)","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS).\n\nThe six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"347","spread":null},{"groupId":"OG001","value":"355","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Six Minute Walk Distance (6MWD)","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS).\n\nThe six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"360","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Worsening Assessment","description":"Definition of clinical worsening included patients who met at least one of the following criteria during the 12 weeks of the study:\n\n1. Death (all causes excluding accident)\n2. Transplantation or atrial septostomy\n3. Clinical deterioration as defined by:\n\n   1. Hospitalization as a result of PAH, or\n   2. greater than or equal to 20% decrease in 6MWD from Baseline (or too ill to walk) and a decrease in WHO functional class And\n   3. Initiation of new PAH specific therapy (i.e., ERA, PDE5-I, prostacyclin)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"World Health Organization Functional Classification for PAH","description":"Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.\n\nClass II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.\n\nClass III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope.\n\nClass IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Borg Dyspnea Score","description":"The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Dyspnea-Fatigue Index","description":"The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"2.4"},{"groupId":"OG001","value":"6.2","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"2.9"},{"groupId":"OG001","value":"5.9","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.5"},{"groupId":"OG001","value":"-0.3","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Symptoms of PAH","description":"Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 12. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.0"},{"groupId":"OG001","value":"0.0","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.9"},{"groupId":"OG001","value":"-0.2","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.0"},{"groupId":"OG001","value":"0.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.0"},{"groupId":"OG001","value":"0.3","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.0"},{"groupId":"OG001","value":"0.3","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.9"},{"groupId":"OG001","value":"0.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.9"},{"groupId":"OG001","value":"0.2","spread":"1.0"}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance by Baseline WHO Functional Classification III or IV","description":"Exploratory efficacy analyses were to determine the effect of Baseline WHO functional class on treatment effect for change in 6MWD.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"333.5","spread":null},{"groupId":"OG001","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"316.5","spread":null},{"groupId":"OG001","value":"354","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance by Baseline WHO Functional Classification: I or II","description":"Exploratory efficacy analyses were to determine the effect of Baseline WHO functional class on treatment effect for change in 6MWD.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":null},{"groupId":"OG001","value":"366","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"391","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance (6MWD) by PAH Etiology: Idiopathic or Heritable PAH","description":"Exploratory efficacy analyses were to determine the effect of PAH etiology (idiopathic/heritable, associated with collagen vascular disease, and other etiologies) on treatment effect for change in 6MWD.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"332.5","spread":null},{"groupId":"OG001","value":"346","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310.5","spread":null},{"groupId":"OG001","value":"380","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance (6MWD) for the Entire Study Population","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data collected from all subjects enrolled in the study, regardless of tablet strength availability at randomization.\n\nThe six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Wk 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference i","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"338.5","spread":null},{"groupId":"OG001","value":"347","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"329.5","spread":null},{"groupId":"OG001","value":"370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance (6MWD) for the Entire Study Population","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at the time of randomization.\n\nThe six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"338.5","spread":null},{"groupId":"OG001","value":"347","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"326.5","spread":null},{"groupId":"OG001","value":"351","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance (6MWD) for the Entire Study Population","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at randomization.\n\nThe six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"338.5","spread":null},{"groupId":"OG001","value":"347","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339.5","spread":null},{"groupId":"OG001","value":"360","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]}]},{"type":"POST_HOC","title":"Six Minute Walk Distance (6MWD) for the Entire Study Population","description":"Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at randomization.\n\nThe six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug.\n\nThe Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"338.5","spread":null},{"groupId":"OG001","value":"347","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339.5","spread":null},{"groupId":"OG001","value":"358","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":77},"commonTop":["headache","nausea","diarrhea","vomiting","flushing"]}}}